Annual Eurocities Conference Held by Espoo Focuses on Cities’ Climate Leadership
31.5.2022 09:00:00 EEST | Business Wire | Press release
At the three-day conference that brings the management of European cities together, the topics discussed include the inclusion of young people, co-creation and cities’ leadership in the work against climate change. The theme of the annual conference, An Era of New Beginnings, consists of three parts, Dream, Act and Lead, through which these topics are studied. The conference attendees include city leadership from Oslo, Rotterdam, Helsinki, Brussels, Stockholm and Munich, among other cities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220530005019/en/
Annual Eurocities conference held by Espoo focuses on cities’ climate leadership. (Photo: Business Wire)
On Friday, one of the keynote speakers will be Executive Vice-President of the European Commission Frans Timmermans, who will introduce the discussion on climate-neutral cities.
“Cities play a key role in the progress towards the EU’s climate goals and building a sustainable future. The annual conference also strengthens the dialogue between cities and the European Commission. However, achieving the goals will be impossible if cities cannot extensively involve operators from all sectors of society. Co-creation and cooperation between the public and private sector are some of the overarching themes of the conference, in addition to climate leadership and young people’s inclusion,” says Milla Ovaska, Head of International Affairs at the City of Espoo.
As a part of the conference and the European Year of Youth, Espoo is organising the Future Mentors programme in which young people living in European cities engage in dialogue with the policymakers of their cities. This is called reverse mentoring.
“We wanted to provide young people with an opportunity to voice their dreams, wishes and concerns about the future of their home city. The decisions that we are making now will have long-term influence, and young people will be the ones living in the future we create. We would like the programme to encourage policymakers to engage in dialogue and give space to new ways of thinking,” says Marianne Julkunen, Partnership Coordinator.
Eurocities Awards to best practices of resident inclusion
On the evening of Thursday 9 June, the conference programme includes the Eurocities Awards ceremony, which showcases the member cities’ projects that have succeeded best in involving their residents and influencing their quality of life. This year’s awards will be given in three categories: ‘Future generations transforming the cities,’ ‘Skills and competences for the future’ and ‘Scalable solutions for positive climate impact.’ The winners will be selected by a five-person jury.
Representatives of the media are cordially invited to attend the annual Eurocities conference on-site at Espoo, Finland. The conference is also available virtually on its website.
#Eurocities2022
#FutureMentors2022
The conference has been created in collaboration with various organisations, all relevant to building future-proof cities and societies. The main partners are Aalto University and VTT. You can find all partners at: eurocities2022.eu/partners.
Eurocities is the key network of European cities for Espoo. Eurocities supervises interests at the level of the EU, generates information about the EU’s funding application rounds and EU legislation, and functions as a peer learning platform for its member cities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005019/en/
Contact information
Eurocities 2022 Espoo conference:
Milla Ovaska, Head of International Affairs, tel. +358 (0)43 824 4911, milla.ovaska@espoo.fi
Future Mentors programme:
Marianne Julkunen, Partnership Coordinator, tel. +358 (0)40 554 3606, marianne.julkunen@espoo.fi
Interview requests for keynote speakers and other media enquiries:
Mari Ala-Mikkula, Marketing and Communications Manager, +358 (0)43 826 7495, mari.ala-mikkula@espoo.fi
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
